頁籤選單縮合
題名 | 癌症病人的熱潮紅=Pharmacotherapy of Hot Flashes in Cancer |
---|---|
作者 | 林玉萍; | 書刊名 | 藥學雜誌 |
卷期 | 32:1=126 2016.03[民105.03] |
頁次 | 頁98-101 |
分類號 | 415.138 |
關鍵詞 | 熱潮紅; 癌症; 藥物治療; Hot flashes; Breast cancer; Prostate cancer; Venlafaxine; Gabapentin; |
語文 | 中文(Chinese) |
中文摘要 | 癌症病人的熱潮紅症狀雖然不至於直接威脅到生命的安危,但是卻大大影響了 生活品質。51-81%的乳癌婦女、69-76%的前列腺癌病人以及85-90%的類癌症狀群 患者 (carcinoid syndrome) 都曾有熱潮紅的經歷。症狀是突然地、而且暫時性的在 臉部和胸部出現發熱、發汗以及潮紅,有時還會伴隨心悸和焦慮。詳細的致病原因 目前還無法確切釐清,可能與雌激素缺乏、下視丘調節障礙和神經傳遞物質改變 有關。目前的治療方式以藥物為主,包括抗憂鬱劑 (venlafaxine 和 citalopram)、抗 癲癇藥 (gabapentin)、腎上腺素拮抗劑 (clonidine) 與黃體素類 (megestrol acetates、 medroxyprogesterone acetate)。藥師在照顧這類病人時除了注意藥物交互作用與不良反 應外,更應指導病人注意嗜中性白血球減少症引起的發熱、藥物引起的熱潮紅與調整 生活形態的重要性。 |
英文摘要 | Hot flashes are not a life-threatening disease but interfere severely with quality of life for women and men with cancer. Prevalence estimates around 51-81% in breast cancer, 69- 76% in prostate cancer, and 85-90% in carcinoid syndrome. Symptoms appear suddenly and transiently as heat feeling and sweating in face and chest, palpitation and anxiety occasionally. Etiology remains unclear but associated with estrogen withdrawal, dysfunction of hypothalamus regulation and neurotransmitters change. Current pharmacotherapy includes antidepressants (venlafaxine, citalopram), anticonvulsants (gabapentin)、antiadrenergics (clonidine) and progestins (megestrol acetates、medroxyprogesterone acetate). Drug interactions, adverse drug effects, distinguishing from neutropenic fever, drug-related flashes and behavior therapy are very important issues for pharmaceutical care in cancer. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。